SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SAN DIEGO, March 01, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it will present at two conferences in March. The presentations will feature a business overview and a scientific update.
- Scott Wolchko, Fate’s President and Chief Executive Officer, will present a Company overview at the 29th Annual ROTH Conference at 2:30 p.m. PT on Monday, March 13, 2017 in Orange County, CA.
- Bob Valamehr, Ph.D., Fate’s VP Cancer Immunotherapy Research, will present a Company scientific update entitled “Using Engineered Pluripotent Cells as a Renewable Source for Off-the-Shelf Cancer Immunotherapy” at the World ADOPT Summit 2017 at 2:30 p.m. GMT on Thursday, March 9, 2017 in London, England.
A live webcast of the 29th Annual ROTH Conference presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay of the presentation will be available on the Company's website for 30 days after the conference.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
